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Psoriasis, a chronic inflammatory skin disease marked by hyper proliferation and
aberrant differentiation of keratinocytes, affects 2–3% of the world’s population.
Research into the pathogenesis of psoriasis has been hampered by the lack of models
that accurately reflect the biology of the psoriatic phenotype. We have previously
reported that East Indian Sandalwood oil (EISO) has significant anti-inflammatory
properties in skin models and hypothesized that EISO might provide therapeutic
benefit to psoriasis patients due to its anti-inflammatory and anti-proliferative properties.
Here we present interim results from an on-going proof-of-concept Phase 2 clinical
trial in which topically applied EISO is demonstrating to be well tolerated and
helpful in alleviating mild to moderate psoriasis symptoms. This led us to evaluate
the ability of EISO to affect the psoriatic phenotype using MatTek Corporation
reconstituted organotypic psoriatic and normal human skin models. EISO had no
impact on the phenotype of the normal skin tissue model, however, EISO treatment
of the psoriasis tissue model reverted psoriatic pathology as demonstrated by
histologic characterization and expression of keratinocyte proliferation markers, Ki67
and psoriasin. These phenotypic affects correlated with suppressed production of
ENA-78, IL-6, IL-8, MCP-1, GM-CSF, and IL-1β. Demonstration of the ability of EISO
to abrogate these psoriasis symptoms in well-characterized in vitro psoriatic tissue
models, supports the hypothesis that the clinically observed symptom alleviation is due
to suppression of intrinsic tissue inflammation reactions in afflicted lesions. This study
presents a systematic approach to further study the underlying mechanisms that cause
psoriasis, and presents data supporting the potential of EISO as a new ethnobotanical
therapeutic concept to help direct and accelerate the development of more effective
therapies.
Keywords: skin organoid, cytokine, chemokine, sandalwood oil, anti-inflammatory, anti-proliferative,
immunomodulation
INTRODUCTION
Psoriasis is a chronic T-cell-mediated autoimmune inflammatory skin disease marked by hyper-
proliferation and aberrant keratinocyte differentiation affecting 2–3% of the world’s population
(Gisondi et al., 2011). Psoriasis patients suffer from impaired quality of life, psychosocial problems
and emotional distress (Strand et al., 2013; Belge et al., 2014; Mease and Armstrong, 2014).
The pathogenesis of psoriasis involves changes in the innate (macrophages, dendritic cells,
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monocytes, neutrophils, endothelial cells, and keratinocytes) and
acquired immune systems (T lymphocytes). The acquired and
innate immune systems interact, resulting in the production
of growth factors, cytokines and chemokines. Such triggers as
injury, infections, stress, and drugs initiate the inflammatory
process resulting in keratinocyte hyperproliferation (Papp et al.,
2012; Schafer, 2012; Dubois Declercq and Pouliot, 2013; Mease
and Armstrong, 2014).
Psoriasis pathogenesis has been described as being caused
by cytokine/chemokine-mediated interactions between
keratinocytes and endothelial cells and the innate and adaptive
immune systems (Heidenreich et al., 2009; Yazdi et al., 2016).
It is thought that in susceptible individuals, a variety of insults
activate release of proinflammatory cytokines such as tumor
necrosis factor-α (TNF-α) and interleukins (ILs) from skin cells.
This activates antigen presenting cells in the skin that migrate to
regional lymph nodes to activate T cells (Dubois Declercq and
Pouliot, 2013; Garcia-Perez et al., 2013). These CD4+, CD8+,
and Th17 T cells then return to the skin, where, through the
release of interferon (INF)-γ, TNF-α, IL-6, IL-22, perforin, and
granzyme B, activate macrophages, neutrophils, dendiritic cells
and promote proliferation of keratinocytes.
The pathogenesis of psoriasis involves genetic, environmental,
and immunological factors that often require long-term
management. Conventional treatments for psoriasis are typically
topical therapies, all of which come with potentially severe
side effects (Schafer, 2012; Ports et al., 2013; Perez, 2013;
Hsu and Armstrong, 2014). Topical therapies available for
mild-to-moderate psoriasis include keratolytics (salicylic acid,
urea); topical retinoids (Tazarotene); topical vitamin analogs
(calcitriol, tacalcitol, and calcipotriol); calcineurin inhibitors
(pimecrolimus and tacrolimus); emollients; dithranol, and tars
(Laws and Young, 2010; Murphy and Reich, 2011). Although
topical corticosteroids remain first-line treatment that help
mitigate all grades of psoriasis, adverse effects such as atrophy,
striae and/or telangiectases prevent their long-term utilization
(Schoepe et al., 2006; Horn et al., 2010; Laws and Young,
2010). The combination of corticosteroids and vitamin D
analogs show superior efficacy as compared to monotherapy;
however, the side effects like skin irritation, erythema and
edema are seen in up to 35% of patients (Menter and Griffiths,
2007). Salicylic acid is safe to use as a treatment for psoriasis
but the long-term use of this drug may result in systemic
salicylic acid toxicity (Lebwohl, 1999). Tazarotene, a retinoid
derivative, is reported to cause skin irritation in up to 30% of
users (Weinstein et al., 2003). While, more recently developed
biological agents offer improved anti-psoriatic therapeutic
responses, they too pose risk of adverse effect, are expensive,
and the potential for development of tolerance or resistance
can limit their use (Gottlieb et al., 2008). Hence there is a need
to develop new therapies (Schafer, 2012; Garcia-Perez et al.,
2013).
Natural products (NPs) represent a vast structural diversity
of bioactive small molecules. Evolved as efficient host defense
agents, NPs remain the best source and inspiration identifying
and developing new drugs (Newman and Cragg, 2012). For
more than 4,000 years, the East Indian sandalwood tree,
Santulum album L. (Santalaceae) has been used in religious
rituals, as fragrance, flavoring and as an Ayurvedic medicine
as management for depression, inflammation reactions, as an
insecticide, an anti-fungal, a sedative and an astringent (Burdock
and Carabin, 2008; So et al., 2010; Zhang and Dwivedi, 2011;
Saraswati et al., 2013; Lee et al., 2015). These antiseptic, anti-
inflammatory and anti-proliferative properties make East Indian
Sandalwood oil (EISO) an attractive potential remedy for various
skin ailments. That EISO’s therapeutic benefits might be due, in
part, to its anti-inflammatory properties are indicated by two
recent studies. A clinical study reported that ESIO treatment
was tolerated well, and reduced lesion counts, in 90% of acne
patients (Moy et al., 2012). This treatment was considered to
have efficacy for relieving acne severity using the Global Aesthetic
Improvement Scale and Evaluator’s Global Severity Score ratings
metrics. The treatment regimen was well tolerated and notable
reductions in lesion counts were observed in patients with more
severe or inflamed lesions. Another demonstrated that EISO,
and its primary constituents, α- and β-santalols can suppress
LPS-mediated pro-inflammatory responses and documented
its impact on cyclooxygenase activity and cytokine/chemokine
expression in skin models (Sharma et al., 2014). We hypothesized
that the ability of EISO and its santalol constituents to suppress
dermal proinflammatory cytokine production would be of use
to treat various inflammation and autoimmune-mediated skin
conditions, including psoriasis.
In this report, we evaluated the ability of a well-characterized
EISO to relieve psoriasis symptoms in a small cohort, to revert
psoriatic characteristics of reconstituted organotypic psoriasis
skin models, and to antagonize production of pro-inflammatory
cytokines and chemokines and markers of proliferation by
comparing responses of parallel normal (non-psoriatic) skin
models.
MATERIALS AND METHODS
Phase 2 Clinical Trial
A single-center, open-label safety, tolerability and efficacy trial
of an anhydrous serum formulation of EISO at one dose
level (10% w/w EISO in a caprylic/capric triglyceride, dimethyl
isosorbide, ethoxydiglycol formulation) for the treatment of mild
to moderate plaque psoriasis in adult subjects was conducted
at Fremantle Dermatology in Australia. The study was carried
out with the recommendations of the Bellberry human research
ethics committee (HREC) in accordance with the national health
and medical research council’s national statement on ethical
conduct in human research (Application No: 2015-12-873) and
the trial was registered with the Australian therapeutic goods
administration (Application ID: CT-2016-CTN-01885-1 v3). All
subjects gave written informed consent in accordance with the
Declaration of Helsinki. The study enrolled 12 subjects over
18 years old, each with a maximum of 10% body surface area
affected by plaque psoriasis. The study medication was applied
twice a day for up to 28 days. The Investigator Global Assessment
(IGA; Langley et al., 2015) was used to evaluate severity of disease
and response to treatment during the 28-day treatment period.
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TABLE 1 | Chemical composition of East Indian sandalwood oil (EISO)a.
Sesquiterpenes EISO (%)b
(Z)-α-Santalol 41–55
(Z)-β-Santalol 16–24
(Z)-Nuciferol 0.8–3.0
epi-β-Santalol 3.5–4.1
(Z)-α-trans-Bergamotol 5.0–6.7
(Z)-β-curcumen-12-ol 0.5–1.9
β-Santalal 1.0–2.4
(Z)-lanceol 1.4–5.6
(E)-β-Santalol 3.5–4.1
β-Santalene 0.7–1.5
aEISO component analysis was performed by Australian Sandalwood Oil Company,
Albany, WA, USA.
b% Average concentration of sesquiterpenes in EISO, mass per volume.
EISO formulation
East Indian Sandalwood oil (lot: PISO-110904SD/SA), an
essential oil obtained by distillation from the heartwood of
plantation-grown S. album trees, was obtained from Santalis
Pharmaceuticals (San Antonio, TX, USA). According to the
Certificate of Analysis, the concentrations of α- and β-santalol
were 49.0 and 20.8%, respectively, and were in compliance
with the International standard for Indian sandalwood oil (ISO
3518:2002). The principal components of EISO are shown in
Table 1. EISO was diluted in dimethyl sulfoxide (DMSO) as
a vehicle, and the final concentration of DMSO used in the
experiments (1:100,000) had no adverse effects on the cells.
Human Full-Thickness Skin Model
Reconstituted full-thickness normal human skin and psoriatic
phenotype (MatTek Corp., Ashland, MA, USA) were incubated
in the manufacturer’s assay media (Grossman et al., 1989;
Nograles et al., 2008) supplemented with or without EISO
0.001–0.002%. Media, with or without supplementation, were
changed every second day. At the specified time points,
specimens were collected for histologic analysis using
H&E and immunohistochemistry (IHC), and the culture
media was collected for cytokine/chemokine enzyme-linked
immunosorbent assay (ELISA) analysis.
Antibodies and Reagents
Monoclonal antibodies (mAb) for Ki67 (8D5) and psoriasin
(47C1068) were purchased from Cell Signaling Tech (Danvers,
MA 01923) and Abcam (Cambridge, UK), respectively. The
FIGURE 1 | East Indian Sandalwood Oil (EISO) improves psoriasis lesion severity. (A) Response of psoriasis lesions from 11 patients to EISO treatment.
Scatter plot shows each patients’ lesion IGA score at start of study (circles, Day 0) and at weekly intervals (squares, Day 7; triangles, Day 14; upside down triangles,
Day 28). The mean score (black horizontal line) ±SEM is shown for each time point. †p < 0.01; ‡p < 0.001 vs. Day 0 initial scores. (B) Representative images from
two patient lesions treated with EISO exhibiting a reduction in the severity of psoriatic plaques after either one (Patient A) or three (patient B) weeks of treatment.
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non-steroidal anti-inflammatory (NSAID), ibuprofen (IB), was
obtained from Sigma–Aldrich (St. Louis, MO, USA). IHC
staining of reconstituted psoriatic and normal human tissue
models was conducted. Deparaffinized sections were subjected
to antigen retrieval, followed by incubation with primary
antibodies (1:500 dilution for Ki67 mAb and 1:200 dilution
for anti-psoriasin mAb). Bound antibodies were detected by
DAB staining using Ventana universal secondary antibody
(Ventana Medical System, Tuscan, Arizona). All stained
slides were digitally imaged at magnification equivalent to
×20. Representative fields were scored by an independent
pathologist.
ELISAs
Sandwich ELISAs for CXCL5 (ENA-78), GM-CSF, IL-1β, IL-6,
IL-8, and MCP-1 (RayBiotech, Norcross, GA, USA) were
performed on culture media from the reconstituted normal
and psoriatic tissue models (with and without treatment with
EISO) according to manufacturer’s instructions. Standard curves
were constructed with supplied standards to allow conversion
of OD450 nm absorbance readings of experimental samples to
pg/ml of the respective factors. All samples were assayed in
triplicate.
Statistical Analysis
Results were compared using a one-way analysis of variance
(ANOVA) followed by a Bonferroni post-test comparing only the
pairs of interest if ANOVA p-values were significant. Enzyme-
linked immunosorbent assays: the post-test results are shown as
∗p < 0.05, †p < 0.01, ‡p < 0.001.
RESULTS
Phase 2 Clinical Study
In nine of the eleven evaluable subjects in the trial, the severity
of psoriatic plaques was reduced by end of study (Figure 1A).
One patient withdrew from the study with a mild adverse event
after 3 weeks on study. The mild skin reaction at the application
site resolved upon withdrawal of the study medication. The
average IGA score of the cohort was significantly reduced by
1 week on study and continued to improve at 2 and 4 weeks
on study. Overall, 64% of the subjects (7/11) demonstrated a
≥1.0 reduction in their IGA score during the 28 day treatment
period. Two examples of lesions prior to and after either one
(Patient A) or three (Patient B) weeks of treatment scored as
markedly improved are presented (Figure 1B). Two additional
patients demonstrated moderate improvement of their psoriatic
plaque. These clinical observations indicated that EISO can
provide symptom relief for psoriasis sufferers, prompting us to
explore the mechanisms underlying EISO’s ability to mediate
these responses.
EISO Treatment of Normal and Psoriatic
Reconstituted Human Skin
To assess whether the clinical observations above could be
recapitulated in an in vitro skin assay, reconstituted organotypic
psoriatic and normal skin preparations were treated in the
absence or presence of EISO. Reconstituted skin samples were
harvested at 2, 4, and 8 days after treatment to assess the impact of
EISO on normal skin or psoriatic phenotype. Histologic analysis
FIGURE 2 | Histology of Reconstituted normal epidermal tissue vs reconstituted psoriatic tissue: H&E stained cross-sections showing reconstituted
skin mimics normal epidermis organization and differentiation histology (A). The tissue morphology of the psoriatic tissue model closely parallels that of
human psoriatic skin (B). The epidermis contains hyper proliferative basal keratinocytes stratum basale (Sb) with regular elongation of the rete ridges (psoriatic
epidermal hyperplasia), and spinous (Ss), granular (Sg), and stratum corneum (Sc) layers. The dermis contains psoriatic fibroblasts (20X). Scale bar = 100 µm.
Frontiers in Pharmacology | www.frontiersin.org 4 March 2017 | Volume 8 | Article 125
fphar-08-00125 March 14, 2017 Time: 17:33 # 5
Sharma et al. Anti-psoriasis Activity of EISO
FIGURE 3 | Normal Epidermal tissue is not affected by EISO treatment. Reconstituted normal skin model, vehicle treated (A), or treated with EISO at 0.001%
(B) or 0.002% (C) for 4 days. Scale bar = 100 µm.
of H&E-stained sections were used to define epidermis and
keratin layer morphology (Figure 2). The epidermis of normal
skin specimens exhibited well-differentiated characteristics of
a defined stratum basale layer under a stratum spinosum
and stratum granulosum layer topped by a discrete stratum
corneum layer (Figure 2A). The epidermis of the psoriatic
skin specimens showed disease characteristics including defined
Rete ridges, a multicellular thick stratum basale layer, poorly
defined stratum spinosum and stratum granulosum layers,
and a thickened stratum corneum layer (Figure 2B). These
observations ae consistent with previous reports indicating that
the MatTek reconstitute skin specimens accurately model normal
and psoriatic epidermal features (Grossman et al., 1989; Nograles
et al., 2008).
Simple observation of H&E-stained samples suggests that
EISO was able to revert psoriatic pathology. Reconstituted
normal epidermal tissue model showed no change in the
epidermal layers after treatment with EISO 0.001–0.002% for
4 days (Figure 3). When EISO treated, the reconstituted psoriatic
tissue exhibited a normalized epidermal architecture (Figure 4).
Epidermal thickness was decreased after just 2 days of treatment
and stratification of the epidermal layers appears to better
recapitulate structures seen in normal skin model.
Psoriasis is characterized by a hyper-proliferative stratum
basale, and using Ki67 as a marker of proliferative cells, we
observed a twofold increase in the number of proliferative cells
in the stratum basale of the reconstituted psoriatic tissue models
(Figure 5B and Table 2). The proliferative index of the EISO-
treated psoriatic skin model samples was suppressed to levels
below that observed in the normal skin model sample. The
number of Rete ridges correlated with Ki67-positive nuclei total
count in psoriatic tissue vs control epidermal tissue (Figure 5B vs.
Figure 5A and Table 2). In addition, the increased keratinocyte
nuclei observed in stratum corneum of psoriatic epidermis
(yellow arrows), indicative of impaired terminal differentiation
of keratinocytes, is decreased in EISO treated psoriatic skin
cultures (Figure 5C: EISO 0.001% and Figure 5D: EISO
0.002%).
The ability of EISO to revert psoriatic pathology is further
documented by immunohistochemical analysis of the cellular
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FIGURE 4 | East Indian Sandalwood Oil treatment restores epidermal architecture of reconstituted psoriatic tissue. Psoriatic tissue vehicle treated (left
images) or treated with EISO (Right images) at 0.002% for 2 days (A), 4 days (B) or 8 days (C). Representative images of decreased epidermal layer thickness (Sc)
and better organized stratum basale (Sb) in the EISO-treated samples. Scale bar = 100 µm.
FIGURE 5 | East Indian Sandalwood Oil treatment (4 days) reverses epidermal inflammation and hyperproliferation in psoriatic skin model.
Reconstituted normal and psoriatic skin samples were cultured in media ±EISO. Immunohistochemical staining of reconstituted psoriasis tissue model showing Ki67
as marker of proliferation restricted to the stratum basale layer (red arrows). (A) Reconstituted normal skin 3D cultures, (B) untreated psoriatic skin, (C) psoriatic skin
+0.001% EISO, (D) psoriatic skin + 0.002% EISO after 4 days. In addition, the increased keratinocyte nuclei observed in stratum corneum of psoriatic epidermis
(yellow arrows) is decreased in EISO treated psoriatic skin cultures. These nuclei are indicative of impaired terminal differentiation of keratinocytes. Scale
bar = 100 µm.
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TABLE 2 | Ki67 average count and Rete ridges count in Psoriasis (PS) and
Epidermal (EPI) control tissue models treated with ±EISO at 0.002% for 4
and 8 days (4D and 8D) for IHC analysis.
ID Ki-67 Avg count ± SEM Rete Ridges
4D-EPI-C 11.25 ± 2.60 0
4D-PS-C 28.75 ± 2.06 21
4D-PS-E 0.002% 1.5 ± 0.57 2
8D-EPI-C 16.00 ± 4.70 1
8D-PS-C 32.75 ± 10.42 27
8D-PS-E 0.002% 1.25 ± 0.62 1
distribution and patterns of expression of the antimicrobial S100-
family member, psoriasin (S100A7) within reconstituted normal
(Figure 6A) and psoriatic specimens (Figures 6B,C). Psoriasin
is known to be localized in hyperplastic epidermis of skin in the
cytoplasm of keratinocytes (Madsen et al., 1991; Morizane and
Gallo, 2012). When the reconstituted psoriatic tissue was treated
with 0.002% EISO for 8 days, psoriasin levels were reduced
(Figure 6).
Anti-inflammatory Properties of EISO on
Reconstituted Psoriasis Tissue
Psoriatic lesions are driven by intrinsic pro-inflammatory reac-
tions. An examination of pro-inflammatory cytokine/chemokine
production measured in conditioned media from control
reconstituted skin models demonstrated that the normal skin
samples produce very low levels of the indicator factors, and were
not affected by EISO or ibuprofen treatment (Figure 7), while
the psoriatic skin models produce significantly higher levels of
all six tested factors after 24 and 48 h in culture (Figure 8). Of
these, IL-1β level was increased>100-fold. Expression of ENA-78
was detected at the highest concentration (69 ng/ml); a >30-fold
increase. MCP-1, IL-8 and GM-CSF levels were elevated≥ 5-fold,
and IL-6 level was increased > 3-fold. Treatment of the psoriatic
tissue model with EISO exhibited equivalent dose dependent
suppression of 6 tested cytokines/chemokines, in some cases
to levels indistinguishable from that seen in the normal skin
model samples (Figure 9). At 0.001% EISO suppressed ENA-
78 by 31%, IL-6 by 73%, IL-8 by 21%, and MCP-1 by 13.6%.
GM-CSF and IL-1β levels were decreased by ≥ 40%. At 0.002%
EISO suppressed ENA-78 by 45%, IL-6 by 75%, IL-8 by 83%,
MCP-1 by 65%, GM-CSF by 80%, and IL-1β by 56%. The robust
suppression of pro-inflammatory cytokine production suggests
that the ability of EISO to revert the psoriatic phenotype might
be due to the previously reported ability of EISO to effectively
suppress epidermal inflammatory cytokine production (Sharma
et al., 2014).
DISCUSSION
Psoriatic lesions are areas of severe inflammation and erythema,
with abnormal differentiation and hyperproliferation of the
keratinocytes that is caused by a pathogenic immune response
driven by reciprocal cytokine, chemokine and growth factor
interactions between cells of the epidermis and the innate
FIGURE 6 | East Indian Sandalwood Oil treatment results in expression level and cellular distribution pattern of psoriasin. Vehicle-treated reconstituted
normal epidermal tissue model (A), vehicle-treated (B), and EISO-treated reconstituted psoriatic skin model (C). Psoriasin is localized in hyperplastic epidermis and
reduced after 8 days of EISO treatment at 0.002% (yellow arrows). Scale bar = 100 µm
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FIGURE 7 | Cytokine/chemokine levels from reconstituted normal epidermal model is basally low and not affected by EISO or IB treatment.
Reconstituted normal epidermal tissue was treated ±EISO and IB at the indicated concentrations for 24 h (left) or 48 h (right). Accumulation of ENA-78, IL-6, IL-8,
MCP-1, GM-CSF, and IL-1β were determined from conditioned media by enzyme-linked immunosorbent assay, expressed as pg/ml.
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FIGURE 8 | Skin model of psoriasis exhibits increased potential key pro-inflammatory cytokines/chemokines. Accumulation of ENA-78, IL-6, IL-8,
MCP-1, GM-CSF, and IL-1β were determined from conditioned media by ELISA from reconstituted normal epidermal tissue (N) and reconstituted psoriasis tissue (P)
after EISO treatment for 24 h (open) and 48 h (filled), expressed as pg/ml, ‡p < 0.001 vs. Normal epidermal tissue (N).
and adaptive immune system (Lowes et al., 2007). A variety
of topical and systemic anti-inflammatory agents, including
phytotherapeutics alone or in combination are used to manage
psoriasis (Rahman et al., 2012). In spite of a range of options,
effective treatment of psoriasis can be challenging. While short-
term treatments provide temporary symptom relief, over time
use of these conventional treatments can cause debilitating side
effects such as immunosuppression, cutaneous atrophy, organ
toxicity and can be carcinogenic (Yuqi, 2005; Traub and Marshall,
2007). While, more recently developed biological agents offer
improved anti-psoriatic therapeutic responses, they too run the
risk of having adverse side effects, are expensive, and might result
in development of resistance or tolerance (Gottlieb et al., 2008).
Natural products may provide effective alternatives for
psoriasis treatment while offering less severe side effect profiles.
Unlike the high target selectivity and activity of current
pharmaceuticals used to treat psoriasis, herbal-derived agents
offer a litany of novel bioactive molecules and the potential
of using several interactive mechanisms of action that are
not found in targeted synthetic agents (Lebwohl et al., 2005;
Weger, 2010; Deng et al., 2013). Lack of regulatory approval
and patient adoption of NPs for psoriasis treatment is due
to the limited information regarding their efficacy and safety
(Herman and Herman, 2016). Clearly promotion of herbal
products as psoriasis treatments must be supported by rigorous
assessment of mechanisms of action, and reliable clinical trials
using standardized therapeutic formulations.
East Indian Sandalwood oil has been used since antiquity for
inflammatory and eruptive skin disorders, but what we know
of its anti-inflammatory properties are anecdotal, and limited
by lack of uniform standardization and characterization
of most preparations. The sesquiterpene alcohols (Z)-
α-santalol and (Z)-β-santalol constitute approximately 70%
of EISO (Christenson et al., 1981). International standard
(ISO 3518:2002(E)) for East Indian Sandalwood oil specifies
41–55% (Z)-α-santalol and 16–24% (Z)-β-santalol. Both santalol
isoforms are biologically active, and are being explored for
possible chemo-preventative, and anti-viral activites (Kaur et al.,
2005; Ochi et al., 2005; Dwivedi et al., 2006; Kim et al., 2006).
Although EISO’s mechanisms of action are not completely
elucidated, santalols derived from EISO have been shown to
have anti-proliferative properties (Lee et al., 2015) as well as
significant anti-inflammatory properties in skin models that
are linked to suppression of prostaglandin and thromboxane
production and cytokine/chemokine expression (Sharma et al.,
2014). We hypothesized that the ability of EISO to suppress pro-
inflammatory events by keratinocytes and dermal fibroblasts,
as well as its antiproliferative properties, would make EISO
useful as a potential treatment of a variety of pathophysiologic
inflammatory and autoimmune skin ailments, including
psoriasis.
Consistent with the afore described properties, the interim
results reported here from a small, on-going proof-of-concept
Phase 2 clinical trial in patients with mild to moderate psoriasis
indicate that a 10% EISO serum formulation administered
topically twice a day for 28 days, is well-tolerated and helpful
in reducing disease severity, as measured by improvement in
the IGA scores (Langley et al., 2015). This proof-of-concept
study was designed to assess efficacy/safety of EISO treatment of
psoriasis lesions. The promising results seen in this test cohort
are being validated in two, 60 patients randomized, placebo-
controlled trials to be conducted in parallel in the US and
Australia. This human trial is being continued, and additional,
larger, placebo–controlled trials are being planned to further
determine the clinical potential for an EISO-based treatment of
psoriasis. These clinical results are supported by in vitro studies
using the same EISO preparation indicating that the clinical
responses are due to the anti-inflammatory properties of EISO.
Using reconstituted normal and psoriatic skin organoid
cultures, we observed improved histologic pathology with
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FIGURE 9 | East Indian Sandalwood Oil suppresses pro-inflammatory cytokines/chemokines production in reconstituted psoriasis skin model.
Reconstituted psoriasis skin models were treated ±EISO or ibuprofen (IB) at the indicated concentrations for 24 h (left) and 48 h (right). Accumulation of ENA-78 (A),
IL-6 (B), IL-8 (C), MCP-1 (D), GM-CSF (E), and IL-1β (F) was determined from conditioned media by ELISA. Cytokines/chemokines accumulation from psoriasis
tissue treated with EISO and IB were compared with the levels of respective Cytokine/chemokine collected from untreated psoriasis tissue, expressed as pg/ml,
∗p < 0.05, †p < 0.01, ‡p < 0.001 vs. Reconstituted psoriasis skin.
Frontiers in Pharmacology | www.frontiersin.org 10 March 2017 | Volume 8 | Article 125
fphar-08-00125 March 14, 2017 Time: 17:33 # 11
Sharma et al. Anti-psoriasis Activity of EISO
improved epidermal stratification, and reduction in number
of and size of Rete ridges, upon EISO treatment. Psoriasis
is characterized by a hyper-proliferative stratum basale, and
using Ki67 as a marker of proliferative cells, we observed
down-regulation of the proliferative index of the EISO-treated
psoriatic skin model samples, to levels below that observed in
the normal skin model. This intriguing observation is consistent
with our previous report that santalols can interact with, and
disrupt microtubules, and so, in addition to acting as an anti-
inflammatory agent, may act to directly suppress cell division
(Lee et al., 2015).
Psoriasin is highly expressed in psoriatic lesions (Madsen
et al., 1991; Morizane and Gallo, 2012), and other hyper
proliferative and inflammatory disorders (Algermissen et al.,
1996). Elevated expression of psoriasin in psoriatic plaques
(Morizane and Gallo, 2012), as well as in other hyper-
angiogenic conditions, has validated it as a marker to assess
in the context of psoriasis (Vegfors et al., 2016). Additionally,
psoriasin is a chemotactic for CD4+ T cells and neutrophils
(Jinquan et al., 1996), and is induced by psoriasis-associated
inflammatory cytokines that include IL-1β, IL-17, IL-22, and
TNF-α (Liang et al., 2006). Our demonstration that EISO
treatment reverted psoriatic pathology by immunohistochemical
analysis of the cellular distribution and expression level of
psoriasin in reconstituted organotypic psoriatic tissue model is
again consistent with the anti-inflammatory properties attributed
to EISO.
An examination of a panel of psoriasis indicator pro-
inflammatory cytokine levels in the reconstituted skin models
demonstrated very low levels in the normal skin model and
profoundly higher levels in the psoriatic skin model, and that
EISO treatment suppressed cytokine/chemokine production, in
some cases to levels indistinguishable from that seen in the
normal skin model samples. While these results are indicators
that EISO can suppress intrinsic inflammatory processes in
psoriatic dermis and epidermis, one of the primary drivers of
psoriasis pathogenesis are a class of T helper cells called Th17
cells (Boniface et al., 2007; Wilson et al., 2007; Lowes et al., 2008;
Glaser et al., 2009; Kagami et al., 2010). These IL-17-producing
leukocytes are thought to initiate the run-away cycle of IL-1β,
IL-6, IL-8, and TNF-α production by the skin cells that leads
to hyperplasia, elevated psoriasin production, and dysregulted
differentiation of the keratinocytes, and further recruitment of
proinflammatory immune system components (van Beelen et al.,
2007; Nograles et al., 2008; Morizane and Gallo, 2012). This
results in recruitment of more IL-17-producing T cells and
neutrophils into the skin. We do not report on IL-17 as the
reconstituted organotypic normal and psoriatic skin models used
the lack immune cell components. Rather, we conclude that the
diseased state is imprinted on the psoriatic dermal fibroblasts
used to construct the organoids, and that EISO is able to
suppress constitutive expression of these downstream cytokines
and chemokines drive the psoriatic phenotype. These preliminary
clinical and in vitro findings strongly support follow-up studies to
expand the duration of the treatments and to directly document
expression of molecular markers indicative of restoration of a
normal epidermal architecture. Subsequent studies with these
models will facilitate further mechanistic understanding of how
psoriatic dermal fibroblasts are able to induce hyper-proliferation
of epidermal cells derived from normal skin.
CONCLUSION
Consistent with the afore described properties, the interim
results from a small, on-going proof-of-concept Phase 2 clinical
trial in patients with mild to moderate psoriasis indicate that
a EISO administered topically, is well-tolerated in reducing
disease severity. EISO treatment of psoriatic reconstituted human
skin, improved histologic pathology with improved epidermal
stratification, reduction in number of and size of Rete ridges
and down-regulation of the proliferative markers like Ki67 and
psoriasin to the levels that observed in the normal skin model.
A panel of psoriasis indicator pro-inflammatory cytokine levels
demonstrated very low levels in the normal skin model and
profoundly higher levels in the psoriatic skin model, and that
EISO treatment suppressed cytokine/chemokine production, in
some cases to levels indistinguishable from that seen in the
normal skin model samples. These clinical results are supported
by in vitro studies using the same EISO preparation indicating
that the clinical responses are due to the anti-inflammatory
properties of EISO in aﬄicted lesions. Determining how the
various factor(s) produced by the dermal fibroblasts drive
the pro-inflammatory response of keratinocytes, what signaling
pathway(s) mediate this response, and finally what node(s) of
these events are directly affected by EISO will be essential to
adoption of EISO-based therapies for treatment of psoriasis.
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